AI Powered Service Seeks to Connect Patients to Trials, Expanded Access Programs

Rare Daily Staff

The global Health technology company myTomorrows said it launched the beta version of TrialSearch AI, a first-of-its-kind artificial intelligence tool to broaden physician insights into clinical trials and expanded access programs in the myTomorrows’ curated database.

Physicians can use the tool to simplify the search process by quickly and accurately identifying opportunities for suitable pre-approval treatments, based on a patient’s profile. The company is currently accepting requests from physicians to trial the tool.

“Our team of researchers and developers designed TrialSearch AI to bring greater speed, transparency, and accuracy to the complex, time-consuming task of manually searching for clinical trials” said Michel van Harten, CEO at myTomorrows. “As a physician who cared for patients diagnosed with cancer, I know first-hand the importance of providing actionable information that can help physicians, patients, and caregivers discover and access potentially life-saving treatments.”

Utilizing TrialSearch AI reduces pre-screening checking time for treating physicians by up to 90 percent, the company said. Physicians can then refer patients to clinical trial sites. They are able to search, review and refer in a matter of minutes by using myTomorrows’ end-to-end platform, the company said.

Physicians can enter a basic, de-identified patient profile into the tool, such as the patient’s condition, age, sex, and country of residence, and other medical information related to patient history in a free-text form. This input is used to identify relevant clinical trial eligibility criteria and to provide a list of clinical trials and, if suitable, expanded access programs, that may be appropriate for the patient.

The physicians then complete a series of minimal manual checks to ensure correctness of the tool’s results. The physician can transparently check what criteria were identified, and if the analysis of the tool is correct to the best of their clinical knowledge. This ensures that physicians are still at the very center of the patient’s treatment discovery journey and no decisions are made without them, the company said.